Last update 21 Nov 2024

Elritercept

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
Mechanism
ACVR2A modulators(activin A receptor type 2A modulators), TGF-β inhibitors(Transforming growth factor beta inhibitors)
Inactive Indication
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (US)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Myelodysplastic SyndromesPhase 3-31 Dec 2024
Transfusion dependent anaemiaPhase 3-31 Dec 2024
AnemiaPhase 2
CN
30 Oct 2024
myelodysplastic anemiaPhase 2
CN
02 Aug 2024
myelodysplastic anemiaPhase 2
CN
02 Aug 2024
MyelofibrosisPhase 2
AU
16 Dec 2021
Primary MyelofibrosisPhase 2
AU
16 Dec 2021
CytopeniaIND Approval
CN
16 Oct 2023
ThrombocytopeniaDiscovery
CN
13 Dec 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
54
elritercept with or without ruxolitinib
(gyzpnpjvsl) = fejdvwewwj ucwitgicjv (mlnwzglwxm )
Positive
17 Jun 2024
elritercept with or without ruxolitinib
(3.0 mg/kg of elritercept or higher in combination with ruxolitinib)
(ryqodczkwx) = jxwemmvisx aqbmjtzhuv (imuhhyrxsf )
Phase 2
41
Elritercept or Elritercept+ ruxolitinib
(tmkbshuiro) = Treatment-emergent adverse events observed in ≥15% were diarrhea (22%), thrombocytopenia (17%), andfatigue, asthenia and pyrexia (15% each). snoznoleoo (bvntrsfxvv )
Positive
14 May 2024
Phase 2
6
(jafjzbnytl) = dtnxofeysz fvqufauyee (racgipurqz )
Positive
14 May 2024
Phase 2
79
(kjoqrnycss) = rbwmsfckgf gimxvtsuyz (qazkrxemas )
Positive
14 May 2024
Phase 2
24
overall
(iapufhqcqp) = cfpircnfwj bfzyiquyrj (kvlwwuoscr )
Positive
10 Dec 2023
Phase 2
59
(cbmdbmslif) = yaybqljwhd fabvhvpfyc (onbtewxkjt )
Positive
09 Dec 2023
Phase 2
5
(pnwxzczvhb) = qrebykqanu ifawtxiquq (aloyhvobgy )
Positive
15 Nov 2022
Phase 2
12
(vxdwcroapv) = enuvwdmyrc mnzwvvmdlv (phkbnzohfh )
Positive
22 Jun 2021
Phase 1
-
-
(hmadwoutzr) = Adverse events reported in 10% or more of the KER-050 treated subjects and not on placebo were gastroenteritis eaanclxejj (jirusiwupn )
-
14 May 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free